AZD1656

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
 
Is this relevant?
2014
2014
AIMS To study the effect of exogenous i.m. glucagon on recovery from controlled insulin-induced hypoglycaemia in patients with… (More)
Is this relevant?
Review
2014
Review
2014
Glucose-phosphorylating enzyme, glucokinase (GK) plays a major role in glucose homeostasis primarily through its regulatory… (More)
Is this relevant?
2013
2013
AIM To investigate the effect of glucokinase activator AZD1656 on glycated haemoglobin (HbA1c) as an add-on to metformin in… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
AIM To assess the glucose-lowering effects of monotherapy with the glucokinase activator AZD1656 in Japanese patients with type 2… (More)
Is this relevant?
2012
2012
OBJECTIVES AZD1656 is a novel glucokinase activator with a postulated dual mechanism of action by activating glucokinase in both… (More)
Is this relevant?
2012
2012
CONTEXT Glucokinase is expressed in the hypothalamus, but effects of glucokinase activators (GKAs) on counterregulatory responses… (More)
Is this relevant?
2012
2012
Oral Glucose Tolerance Test Oral glucose tolerance tests were done on conscious Zucker obese fa/fa rats (age 12-13 weeks or older… (More)
Is this relevant?
2012
2012
AIMS To assess the safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator… (More)
Is this relevant?